IBI3005 not checked

Innovent

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Bispecific Monoclonal Antibody-Camptothecin Derivative Conjugate for Injection (R \& D code: IBI3005)”In the company’s words, NCT07612137 on ClinicalTrials.gov
Tested for
Solid Tumor, Unresectable, Locally Advanced or Metastatic Solid Tumors
Main trialPhase 1/2
“To evaluate the safety and tolerability of IBI3005 combination therapy in participants with advanced solid tumors; to evaluate the antitumor activity of IBI3005 combination therapy in participants with advanced solid tumors.”In the company’s words, NCT07612137 on ClinicalTrials.gov

Other drugs for Solid Tumor

All 2438 drugs for Solid Tumor

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Not yet recruiting 30 Jun 2027 Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Phase 1Recruiting 30 Jun 2027 Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow IBI3005

Following is part of Solo: you see every change to IBI3005 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in